Roche Holding AG (OTCMKTS:RHHBY) Stock Has Consensus Price Target of $60.00 According to Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has received an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $60.00.

RHHBY has been the subject of several recent research reports. Morgan Stanley upgraded Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Friday, August 7th. Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. HSBC reiterated a “hold” rating on shares of Roche in a report on Thursday, September 10th. Finally, Royal Bank Of Canada assumed coverage on shares of Roche in a research report on Tuesday, September 8th. They issued an “outperform” rating for the company.

Roche Price Performance

RHHBY stock opened at $56.78 on Tuesday. The stock’s 50 day simple moving average is $54.86 and its 200 day simple moving average is $52.74. Roche has a fifty-two week low of $40.07 and a fifty-two week high of $60.85. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 0.69.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Woodstock Corp bought a new position in shares of Roche in the third quarter valued at $245,000. GAMMA Investing LLC lifted its position in Roche by 15.3% in the 3rd quarter. GAMMA Investing LLC now owns 33,458 shares of the company’s stock valued at $1,736,000 after acquiring an additional 4,443 shares in the last quarter. Renasant Bank bought a new position in Roche in the 2nd quarter valued at about $210,000. North Star Asset Management Inc. bought a new position in Roche in the 2nd quarter valued at about $1,351,000. Finally, Puzo Michael J acquired a new position in Roche during the 2nd quarter valued at about $1,229,000.

Roche Company Profile

Roche Holding AG is a Swiss healthcare company headquartered in Basel, Switzerland. Founded in 1896, the company operates through two core divisions: Pharmaceuticals and Diagnostics. Roche develops medicines and diagnostic technologies intended to support disease prevention, detection, diagnosis and treatment.

Roche’s pharmaceutical activities focus on areas including oncology, immunology, neuroscience, ophthalmology, hematology and rare diseases. Its portfolio includes biologic and small-molecule medicines, as well as individualized healthcare approaches that use diagnostic information to help guide treatment decisions.

Through its Diagnostics division, Roche provides in vitro diagnostic systems, molecular testing, tissue-based diagnostics, diabetes-care products and laboratory solutions for healthcare providers, laboratories and patients.